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West Germany. Interestingly, up to the 
mid 1990s, NMSC rates among women 
were higher in West Germany than in 
the United States.
Cancers at the border of the skin can 
pose a diagnostic problem because 
the histology of these cancers may not 
allow determination of the origin of 
the cancers, especially if carcinomas 
are undifferentiated and diagnosed at 
late stages. For example, 30.1% of all 
registered vulvar cancers other than 
melanoma in the German Democratic 
Republic from 1976 to 1989 had pen-
etrated the organ border at the time 
of diagnosis (Stang et al., 2005). The 
degree of misclassification of cancers 
at the border of the skin is thus difficult 
to quantify and may be dependent on 
a variety of factors, including diagnos-
tic opportunities such as detail of his-
topathological assessment and stage 
of diagnosis, which most likely have 
changed over recent decades. Another 
problem related to cancers of the border 
of the skin is ICD-miscoding of these 
tumors, especially if cause-of-death 
information is imprecise. For example, 
cancers of the vermillion of the lips 
(ICD-9: 140.0–140.1) can be easily 
miscoded as either skin cancer of the 
lips (ICD-9: 173.0), cancer of the inner 
aspect of the lips (ICD-9: 140.4–140.5), 
or lip cancer that overlaps two or more 
subsites within the three-digit rubric 
(ICD-9: 140.8). Lewis and Weinstock 
included 140.0–140.1 and 140.9 in 
their definition of NMSC (Lewis and 
Weinstock, 2007). Is routine cause-
of-death information accurate enough 
to allow correct distinction between 
these subcategories?
The Rhode Island follow-back study 
did not assess the accuracy of deaths 
coded as NMSC of the lips (ICD-9: 
140.0–140.1 and 140.9) or perianal 
skin (ICD-9: 154.3) and leaves unan-
swered the question of whether inclu-
sion of these deaths in the definition of 
NMSC death is appropriate (Lewis and 
Weinstock, 2004).
In conclusion, Lewis and Weinstock 
provided important new insights into the 
mortality of genital NMSC. These data are 
a good starting point for more detailed 
analyses of the (overall and stage-depen-
dent) incidence and survival of these 
tumors, which could give clues regard-
ing the observed mortality time trends of 
genital NMSC in the United States.
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Why Are Quality of Life Instruments 
Not Recognized as Reference 
Measures in Therapeutic Trials of 
Chronic Skin Disorders?
Jean Jacques Grob1
Patient-reported outcomes, especially heath-related quality of life (HRQOL) 
outcomes, are particularly relevant for chronic skin disorders (CSDs), because 
lesion scores such as PASI are less meaningful in making therapeutic deci-
sions. Patient perception of the disease impact, such as HRQOL, should 
be the main outcome measure in therapeutic trials for CSDs, especially for 
expensive biotherapies. To be credible as reference measures, dermatol-
ogy-specific instruments of HRQOL must generate similar scores in differ-
ent countries and different cultures. Because none of the currently used 
instruments—e.g., the Dermatology Life Questionnaire Index (DLQI) and 
Skindex—fulfills this requirement, it is important to generate new instruments 
or adapt existing ones.
Journal of Investigative Dermatology (2007), 127, 2299–2301. doi:10.1038/sj.jid.5701081
1Department of Dermatology, Hopital Ste. Marguerite, Marseille, France
Correspondence: Dr Jean Jacques Grob, Department of Dermatology, Hopital Ste Marguerite, 270  
Boulevard de Ste Marguerite, Marseille 13009, France. E-mail: jean-jacques.grob@ap-hm.fr
Instruments for recording patient-
reported outcomes, especially heath-
related quality of life (HRQOL) 
instruments, are underutilized in thera-
peutic trials for chronic skin disorders 
(CSDs), such as psoriasis, atopic der-
matitis, and chronic urticaria. They 
are, however, particularly relevant for 
these conditions. Indeed, the severity 
of these disorders is linked mainly to 
their impact on social life, patient com-
fort, and self-perception (Grob et al., 
2005). For example, although decreas-
ing the thickness, redness, or number of 
lesions according to lesion scores is cer-
tainly a valid measure of a drug’s effect 
on skin lesions, it is not a useful mea-
sure of efficacy from a patient’s point of 
view. Localized residual disease on the 
palms, face, or genital regions or a 75% 
improvement of lesion scores (PASI 
75) may still greatly affect HRQOL. A 
patient’s perception of benefits is often 
not proportional to lesion assessments 
COMMENTARY
2300 Journal of Investigative Dermatology (2007), Volume 127
of this sort. Moreover, HRQOL takes 
into account the limitations of compli-
cated treatments (for example, those 
linked to the need for daily applications 
of ointments on large surfaces, which is 
hardly acceptable in 2007). These inter-
fere with compliance and efficacy, but 
they are not revealed in lesion scores 
or by enumerating drug side effects. 
The gap between clinical and HRQOL 
assessments may account for the rela-
tive failure of some drugs once they 
reach the market, despite favorable tri-
als based on clinical scores.
A physician’s key objective when 
discussing therapeutic decisions 
(Katugampola et al., 2005) with a 
patient who has a CSD is to improve 
quality of life and, more general- 
ly, patient satisfaction. Dermatology-
specific HRQOL instruments are thus 
adapted to assess treatment from the 
patient’s perspective.
In this context, we ask ourselves 
why improvement of HRQOL is not 
used as the primary objective in most 
therapeutic trials for CSDs. The answer 
is its lack of credibility, for several rea-
sons. First, clinical scores are supposed 
to be objective, reliable, and reproduc-
ible, although they are often a “subjec-
tive” assessment of “objective” lesions. 
Conversely, an objective measure of 
subjective feelings such as HRQOL 
is harder to conceive of as reliable, 
even when HRQOL instruments have 
been validated. Second, it is difficult 
to know what a given HRQOL score 
means in real practice, and efforts 
must be made to translate HRQOL 
into practical information (Hongbo et 
al., 2005). Third, there are doubts that 
these instruments measure the same 
thing in different settings. Drug agen-
cies are suspicious about HRQOL 
data. Unfortunately, this suspicion may 
not be unjustified, because most of the 
dermatology-specific HRQOL instru-
ments commonly used in therapeutic 
trials in different countries have not 
demonstrated what such instruments 
must demonstrate: a cross-equivalence 
of each measure in all locations. Taken 
together, these reasons explain why 
“prehistoric” instruments such as PASI, 
the scores of which are generally thera-
peutically irrelevant, are still the basis 
of evaluations in CSDs.
The Dermatology Life Questionnaire 
Index (DLQI), the most extensively used 
dermatology-specific HRQOL instru-
ment in dermatology, was developed 15 
years ago, and at that time it was con-
sidered visionary. There is considerable 
evidence that DLQI is a good instru-
ment, but the methodologies of generat-
ing and validating HRQOL instruments 
have improved so much that the DLQI 
is now what a computer from 1990 is 
compared with a 2007 computer. The 
general attitude is, however, to employ 
DLQI in most therapeutic trials, for 
fear that any change in the convention 
would raise suspicions. Additional sec-
ond- and third-generation dermatology 
HRQOL instruments have been generat-
ed for different countries and languages 
(Chren et al., 1996; Grob et al., 1999; 
Schäfer et al., 2001). As a result of the 
worldwide diffusion of the English lan-
guage and the higher impact of English-
language journals, instruments generat-
ed in English-speaking countries (DLQI 
from the United Kingdom and Skindex 
from the United States) are the basis of 
dermatology-specific HRQOL measure-
ments throughout the world, because 
they have been translated and tested 
in many languages. In a “systematic” 
review of all HRQOL instruments avail-
able for psoriasis, De Korte et al. (2003) 
studied only those written in English. As 
a consequence, most worldwide der-
matology trials using HRQOL accept 
the unexpressed hypothesis that a good 
translation of DLQI or Skindex—i.e., 
instruments using social and psycholog-
ical constructs validated in the United 
Kingdom or United States—will work 
equally well in any country in Europe 
or even in the Middle East or Asia 
(AlGhamdi and AlShammari, 2007; 
Higaki et al., 2002). Despite the dem-
onstrated measurement reliability of 
Skindex in Japan (Higaki et al., 2002), it 
is likely that a translation into Japanese 
of a U.S. instrument is less meaning-
ful, reliable, or sensitive for therapeutic 
trials in Japan than would be a well-
constructed HRQOL instrument gener-
ated in Japanese. It is also likely that the 
American instrument would not give 
the same results for HRQOL impact in 
the United States and Japan.
The study presented in this issue by 
Nijsten et al. (2007) is exactly the type 
of study needed for HRQOL measure-
ments to become credible as major 
outcome measures for dermatologi-
cal trials. Using differential item func-
tioning, the authors studied different 
translations of DLQI and Skindex for 
psoriasis patients from different coun-
tries. Nijsten and colleagues are the first 
to demonstrate what many research-
ers suspected, i.e., that neither instru-
ment is suitable for multinational trials. 
Although their different translations are 
widely used in many countries, and 
although they have been shown more 
or less to measure disease severity 
everywhere, each of these instruments 
scores differently in different countries 
for the same level of HRQOL impair-
ment. Thus, DLQI, Skindex, and prob-
ably most similar instruments, despite 
their measurement reliability, are 
monocultural instruments. This type 
of study does not discredit interest in 
patient-reported-outcome and HRQOL 
instruments, but it underlines the criti-
cal need for researchers to generate 
adequate instruments, whether de novo 
or from pre-existing ones. In multina-
tional trials or in assessing the results 
of trials conducted in different coun-
tries, we need instruments that provide 
similar changes in scores for the same 
delta in HRQOL, whatever the coun-
try, whatever the time, and whomever 
the patient. This is particularly critical 
now, because many new and expen-
sive drugs are in development. Their 
costs must be justified by a supplemen-
tary benefit from the patient’s point of 
view. This requires multinational trials, 
and the conclusions must be valid in 
any country.
The concept of cross-cultural equiv-
alence is a difficult one, however. 
Despite a perfect translation and cross-
translation, patients with a similar 
HRQOL from different countries still 
score differently on different items, not 
only because they understand the same 
question in a different way due to cul-
|Developing cross-cultural instruments of patient-reported 
outcomes is essential.
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tural interpretations but also because 
they may answer differently due to 
divergent social norms. Moreover, 
similar improvements or worsenings 
as a result of treatment can also have 
a different impact on HRQOL because 
of different degrees of coping with 
disease in the various cultures. This 
variability is highly interesting from 
a societal point of view and very 
informative about the doctor–patient 
relationship. However, from a mea-
surement point of view in therapeutic 
trials, we must find the same score dif-
ference for the same HRQOL differ-
ence. Several possibilities are open: 
co-generating a polycultural instru-
ment from different countries, devel-
oping algorithms to adjust the results 
of different translations of pre-exist-
ing instruments,or standardizing the 
results obtained with different well-
constructed national instruments.
The “pioneer period” of HRQOL in 
dermatology is over. Let’s build a new 
era in assessment of treatment of CSDs 
based on cross-cultural instruments of 
patient-reported outcomes.
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